News | February 14, 2022
Divi’s Labs Q3 driven by custom synthesis; margins sustainable: ICICI Direct
Key takeaways of recent quarter & conference call highlights
Key takeaways of recent quarter & conference call highlights
Key takeaways of recent quarter & conference call highlights
Sun Pharma’s Q3FY22 operational performance was in line with I-direct estimates with sustained momentum and good growth across businesses
ICICI Direct analysis of Dr Reddy’s Q3FY22 results
ICICI Direct’s analysis of Cipla’s Q3FY22 results
The management guided for ARV API & formulation demand to be normalised from Q4FY22 and reiterated the aspiration of US $ 1 billion in sales by FY23: ICICI Direct
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
Astec LifeSciences has reported its financial performance for the quarter ended December 31, 2021
ICICI Direct gives a preview on the earnings narrative for Q3FY22
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
Subscribe To Our Newsletter & Stay Updated
